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ORIGINAL INVESTIGATION

HEALTH CARE REFORM

Forced Smoking Abstinence
Not Enough for Smoking Cessation
Jennifer G. Clarke, MD, MPH; L. A. R. Stein, PhD; Rosemarie A. Martin, PhD; Stephen A. Martin, MD;
Donna Parker, ScD; Cheryl E. Lopes, PhD; Arthur R. McGovern, PhD; Rachel Simon, BS;
Mary Roberts, MS; Peter Friedman, MD, MPH; Beth Bock, PhD

Importance: Millions of Americans are forced to quit
smoking as they enter tobacco-free prisons and jails, but
most return to smoking within days of release. Interventions are needed to sustain tobacco abstinence after release from incarceration.
Objective: To evaluate the extent to which the WISE
intervention (Working Inside for Smoking Elimination), based on motivational interviewing (MI) and cognitive behavioral therapy (CBT), decreases relapse to
smoking after release from a smoke-free prison.
Design: Participants were recruited approximately 8
weeks prior to their release from a smoke-free prison and
randomized to 6 weekly sessions of either education videos (control) or the WISE intervention.
Setting: A tobacco-free prison in the United States.
Participants: A total of 262 inmates (35% female).
Main Outcome Measure: Continued smoking abstinence was defined as 7-day point-prevalence abstinence
validated by urine cotinine measurement.
Results: At the 3-week follow-up, 25% of participants

in the WISE intervention (31 of 122) and 7% of the control participants (9 of 125) continued to be tobacco ab-

T

Author Affiliations are listed at
the end of this article.

stinent (odds ratio [OR], 4.4; 95% CI, 2.0-9.7). In addition to the intervention, Hispanic ethnicity, a plan to
remain abstinent, and being incarcerated for more than
6 months were all associated with increased likelihood
of remaining abstinent. In the logistic regression analysis, participants randomized to the WISE intervention
were 6.6 times more likely to remain tobacco abstinent
at the 3-week follow up than those randomized to the
control condition (95% CI, 2.5-17.0). Nonsmokers at the
3-week follow-up had an additional follow-up 3 months
after release, and overall 12% of the participants in the
WISE intervention (14 of 122) and 2% of the control participants (3 of 125) were tobacco free at 3 months, as confirmed by urine cotinine measurement (OR, 5.3; 95% CI,
1.4-23.8).
Conclusions and Relevance: Forced tobacco abstinence alone during incarceration has little impact on
postrelease smoking status. A behavioral intervention provided prior to release greatly improves cotinineconfirmed smoking cessation in the community.
Trial Registration: clinicaltrials.gov Identifier:

NCT01122589
JAMA Intern Med. 2013;173(9):789-794.
Published online April 8, 2013.
doi:10.1001/jamainternmed.2013.197
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to over 400 000 deaths
annually. 1 It is a major
contributor to cancer and
heart disease risk and is
the leading cause of preventable morbidity, mortality, and health expense in
the United States resulting in an estimated $157 billion in related annual
health and economic costs. 2 Quitting
smoking reduces the risk of developing
smoking-related illnesses and the morbidity and mortality associated with
these illnesses. In 2010, approximately
45.3 million American adults smoked,
an overall prevalence of 19.3%.3
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One in 8 American smokers pass
through prisons and jails annually,4 and
since the announcement of the negative
health consequences of secondhand
smoke, correctional facilities are increasingly becoming tobacco free: approximately 60% have complete smoking bans

See Invited Commentary
at end of article
(no tobacco products allowed anywhere
in the facility by inmates or staff ).5 Despite this, 97% of inmates return to smoking as soon as they are released back into
the community.4,6 Smoking among pris-
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PARTICIPANTS
312 Assessed for eligibility

50 Excluded
39 Did not meet
inclusion criteria
11 Declined to participate

262 Randomized

130 WISE MI/CBT intervention
8 Excluded
5 No baseline data
3 Never released
122 Final

132 Control
7 Excluded
4 No baseline data
3 Never released
125 Final

3-Week follow-up
(188/122) 96.7%

3-Week follow-up
(110/125) 88.0%

Participants were recruited by research assistants (RAs) from
a large state correctional facility in the northeastern United States
(Figure 1) in which no tobacco products are allowed on site
by inmates or staff, and no pharmacotherapy or behavioral
therapy is routinely offered for smoking cessation. Sentenced
men and women were eligible for screening if they were to be
released within the next 8 weeks. In a confidential setting, RAs
explained the study and that participation was completely voluntary. Potential participants were eligible if they were 18 years
or older, smoked 10 or more cigarettes per day prior to incarceration, and spoke English. Once a potential participant was
determined to be eligible and willing to participate in the study,
the informed consent process was completed. All participants
received an American Heart Association smoking-cessation pamphlet, a list of community resources, and study contact information.

SAMPLE SIZE AND ATTRITION
31 Nonsmokers

9 Nonsmokers

3-Month nonsmoker
follow-up rate
(23/31) 74.2%

3-Month nonsmoker
follow-up rate
(5/9) 55.6%

Figure 1. Participant flowchart. CBT indicates cognitive behavioral therapy;
MI, motivational interviewing; WISE, Working Inside for Smoking
Elimination.11

oners is approximately 3 times that of the general population,7 and minorities, poor, undereducated, and mentally ill individuals are all overrepresented in correctional
facilities.8 Despite the scale of this problem, few studies
have addressed the needs of incarcerated smokers.
Many successful interventions have been developed
for smoking cessation, but the success of smoking relapse–
prevention interventions is limited. Moreover, the available smoking-cessation and relapse-prevention treatments do not address the unique and specific needs of
incarcerated men and women who have been tobacco free
for months to years (forced-abstinent smokers), who have
completed the physical withdrawal from nicotine, and
who are returning to environments where tobacco is available.9 Effective smoking relapse–prevention interventions for this population will enhance our ability to attain the Healthy People 2020 goal of decreasing smoking
rates to 12% among adults.10
Project WISE (Working Inside for Smoking
Elimination)11 is a randomized clinical trial of a smoking abstinence intervention based on motivational interviewing (MI) and cognitive behavioral therapy (CBT),
which was developed to target the specific needs of inmates in a smoke-free prison about to be released to the
community.
METHODS
Complete details of the methods for this study have been described elsewhere.11 Approvals from the institutional review
board and the office for human research protections were obtained prior to any study activities. To further protect study participants, a certificate of confidentiality was obtained.

Of the 312 people screened for the study, 2 did not speak English, 30 did not smoke ⱖ10 cigarettes/d prior to incarceration,
7 had more than 8 weeks until release, 2 were homeless and
could not provide any contact information for follow-up, and
1 was not going to live in the follow-up area). Of the 273 eligible persons, 262 (96.0%) agreed to participate and completed the consent procedure. Of the 262 enrolled and randomized at baseline, 15 were excluded (from this report), 9
because of a computer error that did not save data from the baseline questionnaire and 6 because they were still incarcerated
at the end of the study and hence could not be assessed for smoking after release. Of the remaining 247 participants, 228 (92.3%)
completed the 3-week postrelease follow-up assessment. Nonsmokers at the 3-week follow-up were invited to return for a
3-month follow-up and 70% completed this assessment (28 of
40). Participants lost to follow-up were analyzed as smokers.

PROCEDURES
Following baseline assessment, participants were randomly assigned to either receive the WISE intervention or watch control videos. Randomization was stratified by sex, number of cigarettes smoked in the 30 days prior to incarceration (⬍20
cigarettes/d vs ⱖ20 cigarettes/d), and postrelease smoking plans,
as previously described.11 Each study condition comprised 6
sessions that took place over approximately 6 weeks prior to
release. A 3-week postrelease follow-up, assessment included
taking a urine sample for cotinine evaluation, a computerized
assessment, and a timeline followback (TLFB) procedure12,13
to determine smoking behaviors on each day following release
from prison. Participants who were confirmed tobacco abstinent at 3-week follow-up were asked to return for a 3-month
postrelease assessment.

INTERVENTIONS
WISE Intervention
Sessions 1 and 6 of the WISE intervention involved MI, and in
sessions 2 through 5, participants received CBT.
Three RAs (with bachelor’s or equivalent degrees) received
approximately 24 hours of training, including didactic instruction, role playing, and working with pilot participants. The RAs
were matched with sex-concordant participants. Two PhDlevel supervisors rated sessions to criteria using the Motivational Interviewing Treatment Integrity system, version 3.1.1,14
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and a key elements checklist for CBT sessions prior to RA contact with participants. Supervision was conducted twice per
month and when treatment fidelity fell below criteria. Additional coaching was provided until sessions met standard. Sessions were 30 to 60 minutes long, and all were recorded. A random 10% of sessions were coded for fidelity by supervisors, and
10% of those were double coded. There was over 90% agreement in the coding in terms of proficient vs nonproficient, and
85% were proficient.
The research counselors’ therapeutic style and protocol were
based on the principles of MI, with a focus on empathy, not
arguing, developing discrepancy, self-efficacy, and personal
choice.15 The CBT sessions taught participants to recognize specific environmental and affective events (triggers) that occur
prior to smoking and to identify behavioral and cognitive strategies to cope with these triggers. Additional brief telephone sessions were conducted at approximately 24 hours and 7 days
after the individual’s release. These sessions included elements of both MI and CBT in an effort to maintain and enhance motivation and use of skills after release.

Control Condition
The control videos included a variety of health-related topics
(eg, managing chronic pain) but did not target smoking cessation and were matched with the WISE intervention for frequency and duration of contact. To maintain frequency and duration of contact, telephone calls were scheduled for
approximately 24 hours and 7 days after release; these calls verified contact information and assessed smoking status.

ANALYSES
We examined baseline differences between conditions on demographic and smoking variables using 2 tests of proportions for
categorical variables and t tests for continuous variables. To be
considered having completed the study, a participant had to
complete a 3-week follow-up interview and provide a urine
sample. We examined other variables that might predict outcome in this sample by comparing those with sustained abstinence to those who smoked. These included sex, age, years of
education, race/ethnicity, measures of affective symptoms and
vulnerability (CES-D, Perceived Stress Scale), prison drug treatment, and smoking-related variables including FTND score, cigarettes smoked per day prior to incarceration, time since smoked
daily, age started smoking daily, number of years of daily smoking, smoking plans after release, presence of smoking-related
medical condition, and presence of a spouse/partner who
smokes.
Analyses of sustained abstinence at 3 weeks after release used
the full intention-to-treat sample and used logistic regression.
In the first model, we entered treatment group only. The second model adjusted for other variables related to sustained abstinence with a level of significance set at P⬍.10. Time since
smoked daily was dichotomized (ⱖ6 months vs ⬍6 months)
because it was highly skewed.
We next conducted discrete-time survival analysis using Cox
proportional hazards regression models to test the hypothesis
that the risk of returning to smoking was significantly higher
for participants randomized to the control condition compared with participants in the WISE intervention. All analyses
were conducted using SPSS statistical software, version 20 (IBM
Corp).

MEASURES
Full assessments, each taking about 60 minutes, occurred at
baseline and at 3 weeks following release. The RAs phoned participants at 24 hours and 7 days after release for brief discussion, and prior to discussion, smoking status was assessed. Assessments at baseline and 3-week follow-up were conducted
using audio computer-assisted self-interviews. Assessments included demographics, smoking history and dependence (Fagerström Test for Nicotine Dependence [FTND] modified to reflect time prior to incarceration),16 subjective stress (Perceived
Stress Scale),17 presence or absence of smoking-related illnesses (asthma, diabetes, hypertension, stroke, or heart attack),
and depressive symptoms (Center for Epidemiologic Studies
Depression Scale [CES-D]).18 Participation in a prison drug treatment program was assessed with the question “have you participated in a drug treatment program?” Many prison drug treatment programs use CBT and MI (similar to the WISE
intervention).
Intention to remain tobacco free was measured using a
6-point scale and dichotomized: responses of “I plan to smoke
when I get out of here and never plan to quit” to “I will probably smoke when I get out of here” were classified as “plans to
smoke upon release.” Responses of “I probably won’t smoke
when I get out of here” to “I have made plans to not smoke
when I get out. and I will never smoke again” were classified
as “plans to not smoke upon release.” At the 3-week followup, a urine sample was obtained to test for cotinine and other
substance use, and a detailed TLFB12,13 was administered to assess tobacco use. An additional urine cotinine measurement was
obtained 3 months after release from participants who tested
negative for cotinine at the 3-week follow-up. Continued smoking abstinence was defined as testing negative for cotinine (urinary cotinine level, ⬍200 ng/mL) and reporting no smoking
in the previous 7 days; all others were considered smokers.19

RESULTS

PARTICIPANT CHARACTERISTICS
The sample (N = 247) comprised the following racial/
ethnic background: 20.1% Hispanic, 17.6% black, 52.0%
white, and 10.2% self-identified as other and did not differ by intervention group (Table 1). Most participants
were men (65.2%); mean age was 35.6 years; and the mean
time since the last cigarette was 1.5 years. Intervention
groups did not differ significantly at baseline on depression, stress, demographic, or smoking variables (Table 1).
All 6 WISE intervention sessions were completed by
83.3%, with 11.9% completing 3 or fewer sessions.
Analysis comparing WISE and control participants
on confirmed smoking status 3 weeks after release found
participants randomized to the WISE intervention were
4.4 (95% CI, 2.0-9.7) times more likely to remain tobacco abstinent than those randomized to the control condition (Table 2). Significant differences (P ⬍ .10) were
found between smokers and nonsmokers: Those not
smoking at the 3-week follow-up started smoking when
they were older (age 17.3 vs 15.4 years) (P = .02), smoked
for fewer years (16.6 vs 19.9 years) (P = .06), were more
likely to have participated in prison drug treatment (63.2%
vs 47.3%) (P = .07), had gone longer since smoking regularly (2.5 vs 1.4 years) (P = .06), were more likely to be
Hispanic (33.3% vs 17.6%) (P = .02), and planned not
to smoke after release from prison (62.5% vs 46.1%)
(P = .06). We therefore controlled for these variables in our
multivariate logistic regression.
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Table 2. Nonsmokers vs Smokers at 3-Week Follow-up a

Table 1. Participant Randomization
and Baseline Characteristics a

Characteristic
Race/ethnicity
White
Hispanic
Black, non-Hispanic
Other
Sex
Male
Female
Smoking plans
Plan to smoke after release
Plan to not smoke after release
Education level completed
⬍High school
High school
⬎High school
Reported health status
Poor-fair
Good-excellent
In-prison drug treatment
Smoking-related medical
conditions
Age, y c
Age started smoking daily, y c
Years of smoking c
Time since smoked daily, y c
Cigarettes/d prior to prison,
No. c
FTND c
PSS c
CES-D c

Total
(n = 247)

WISE b
(n = 122)

Control
Video
(n = 125)

127 (52.0)
49 (20.1)
43 (17.6)
25 (10.2)

63 (51.6)
26 (21.3)
21 (17.2)
12 (9.8)

64 (52.5)
23 (18.9)
22 (18.0)
13 (10.7)

161 (65.2)
86 (34.8)

80 (65.6)
42 (34.4)

81 (64.8)
44 (35.2)

126 (51.2)
120 (48.8)

65 (53.3)
57 (46.7)

61 (49.2)
63 (50.8)

157 (64.6)
49 (20.2)
37 (15.2)

81 (66.4)
21 (17.2)
20 (16.4)

76 (62.8)
28 (23.1)
17 (14.0)

75 (30.7)
169 (69.3)
119 (49.8)
89 (36.0)

41 (33.6)
81 (66.4)
56 (47.1)
44 (36.1)

34 (27.9)
88 (72.1)
63 (52.5)
45 (36.0)

35.6 (9.2)
15.7 (4.5)
19.4 (10.0)
1.5 (3.4)
21.7 (11.7)

35.4 (9.4)
15.6 (4.7)
19.1 (10.0)
1.6 (3.4)
20.7 (10.6)

35.7 (9.0)
15.9 (4.3)
19.7 (10.0)
1.5 (3.5)
22.6 (12.8)

5.1 (2.3)
21.8 (6.3)
12.7 (5.4)

5.2 (2.2)
21.5 (7.0)
12.4 (5.6)

5.1 (2.4)
22.2 (5.6)
13.0 (5.3)

Abbreviations: CES-D, Center for Epidemiologic Studies Depression
Scale18; FTND, Fagerström Test for Nicotine Dependence,16 modified to reflect
time prior to incarceration; PSS, Perceived Stress Scale17; WISE, Working
Inside for Smoking Elimination.11
a Unless otherwise indicated, data are reported as number (percentage) of
participants.
b P ⬎ .20 for all treatment group differences.
c Data reported as mean (SD) values.

In the multivariate logistic regression (Table 3), randomization to the intervention group remained a significant predictor of abstinence at 3 weeks (odds ratio [OR],
6.6; 95% CI, 2.5-17.0) compared with those randomized to the control condition. Hispanic ethnicity was also
associated with greater tobacco abstinence at 3 weeks (OR,
3.2; 95% CI, 1.1-8.7), as was not smoking for 6 or more
months (OR, 4.6; 95% CI, 1.7-12.4) and planning to not
smoke (OR, 1.6; 95% CI, 1.2-2.3).
Participants who were abstinent at their 3-week follow-up (n = 40) were reevaluated at 3 months. In the control group, 2.4% (3 of 125) were cotinine-confirmed abstinent compared with 11.5% (14 of 122) in the
intervention group (OR, 5.3; 95% CI, 1.4-23.8). However, follow-up data were obtained on only 28 (70%) of
the 40 nonsmokers.
An adjusted survival curve using Cox proportional hazards model is depicted in Figure 2 and includes days
to first cigarette from the TLFB data. The first day in the
community was the highest-risk day, when most participants relapsed to smoking. After day 1, the rate of re-

Nonsmoker
(n = 40)

Characteristic
Intervention condition
WISE intervention
Control video
Female
Education level completed
⬍High school
High school
⬎High school
Race/ethnicity
White
Hispanic
Black, non-Hispanic
Other
Smoking plans
Plan to smoke upon release
Plan to not smoke upon release
Smoking-related medical conditions
Spouse/partner smokes
Drug use prior to incarceration
In prison drug treatment
Age, y b
Age started smoking daily, y b
Years of smoking b
Time since smoked daily, y b
Cigarettes/d prior to prison, No. b
FTND b
PSS b
CES-D b

Smoker
(n = 207)

31 (25.4)
9 (7.2)
14 (35.0)

91 (74.6) c
116 (92.8) c
72 (34.8)

24 (61.5)
9 (23.1)
6 (15.4)

133 (65.2)
40 (19.6)
31 (15.2)

17 (43.6)
13 (33.3)
5 (12.8)
4 (10.3)

110 (53.7)
36 (17.6) d
38 (18.5)
21 (10.2)

15 (37.5)
25 (62.5)
17 (42.5)
18 (51.4)
35 (87.5)
24 (63.2)
35.2 (9.4)
17.3 (5.6)
16.6 (9.1)
2.5 (2.4)
19.0 (9.5)
4.9 (2.3)
21.5 (6.1)
12.3 (4.9)

111 (53.9) e
95 (46.1)
72 (34.8)
102 (60.4)
194 (93.7)
95 (47.3) e
35.7 (9.2)
15.4 (4.2) d
19.9 (10.1) e
1.4 (3.6) e
22.1 (12.1)
5.2 (2.3)
21.9 (6.3)
12.8 (5.5)

Abbreviations: CES-D, Center for Epidemiologic Studies Depression
Scale18; FTND, Fagerström Test for Nicotine Dependence,16 modified to reflect
time prior to incarceration; PSS, Perceived Stress Scale17; WISE, Working
Inside for Smoking Elimination.11
a Unless otherwise indicated, data are reported as number (percentage)
of participants.
b Data reported as mean (SD) values.
c P ⬍ .01 for differences between smokers and nonsmokers.
d P ⬍ .05 for differences between smokers and nonsmokers.
e P ⬍ .10 for differences between smokers and nonsmokers.

lapse declined sharply, with the intervention group maintaining significantly better survival (P = .001). In the
survival model examining days to first smoking lapse, the
main effect of treatment condition was significant, ␤ (SE),
0.56 (0.16); hazard ratio, 1.75 (P = .001), indicating that
the risk of smoking after release was over 1.75 times
greater for those in the control condition than for those
in the WISE intervention.
COMMENT

To our knowledge, this is the first study to demonstrate
an effective intervention to prevent smoking relapse after release from a prison with a complete tobacco ban.
The abstinence rates were 25.4% and 7.2% at 3 weeks
and 11.5% and 2.4% at 3 months in the WISE intervention and control groups, respectively. The situation of
forced tobacco abstinence during incarceration is unique
in that incarcerated people have no choice about abstaining from tobacco; they have completed nicotine withdrawal; and they face reexposure to tobacco once released. Therefore, comparisons with other interventions
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Table 3. Logistic Regression

WISE intervention
In prison ⬎6 mo
Hispanic
Smoking plans
Cigarettes/d prior to prison,
No.
In-prison drug treatment

␤ (SE)

P
Value

OR (95% CI)

1.9 (0.5)
1.5 (0.5)
1.2 (0.5)
0.5 (0.2)
⫺0.03 (0.02)

⬍.01
⬍.01
.03
⬍.01
.10

6.6 (2.5-17.0)
4.6 (1.7-12.4)
3.2 (1.1-8.7)
1.6 (1.2-2.3)
1.0 (0.9-1.0)

0.6 (0.5)

.16

Cumulative Proportion of Nonsmokers, %

Variable

100

1.9 (0.8-4.6)

Abbreviations: OR, odds ratio; WISE, Working Inside for Smoking
Elimination.11

Treatment Group∗
Control
Intervention

80

60

40

20

0
0

5

10

15

20

25

Time to First Cigarette, d

are limited in their application and scope. Many smokingcessation interventions focus on setting a quit date and
remaining abstinent; however, in this setting the quit date
is forced by someone other than the tobacco user. For
those who had smoked prior to incarceration, there is
no choice in quit date, and it is only on the date of release when there is a choice to be made about remaining
abstinent or returning to smoking.
Results of the WISE intervention are better than those
found in many other studies on behavioral intervention
for smokers. On average, MI leads to an increase in smoking cessation with a risk reduction (RR) of 1.27.20 Individual counseling is more effective than the control condition with an RR for smoking cessation of 1.39 (95%
CI, 1.24-1.57).21 Our results may be greater because of
the enforced abstinence prior to the intervention. In addition, participants who had not smoked for 6 months
or longer at the time of the intervention were 4.6 times
as likely to be abstinent at 3 weeks compared with those
who smoked within the past 6 months. This suggests that
prolonged forced abstinence can improve smoking outcomes. However, without intervention, only 2.4% of participants remained tobacco free at 3 months after release. Results may also be related to the relatively brief
follow-up period; future research should examine this issue. Similar to other studies, our study found the early
postrelease period to be an extremely high-risk time,22,23
with more than 60% of control participants relapsing to
smoking the first day out.
We chose not to include pharmacotherapy in this intervention because we could find no evidence supporting the use of medications after prolonged tobacco abstinence. Contraband tobacco products exist in prisons,
but the majority of inmates will not use them because of
the high costs ($10 per cigarette, according to several inmates) and consequences.24 The higher the level of security, the more difficult it is to access cigarettes. Medications have enhanced smoking cessation: varenicline
showed an RR of 2.27 (95% CI, 2.02-2.55)25; bupropion
RR, 1.69 (95% CI, 1.53-1.85)26; and nicotine replacement therapy RR, 1.58 (95% CI, 1.50-1.66).27 While these
studies all had longer follow-up periods, the effect of our
behavioral intervention is comparable.
One of the national health objectives for 2020 is to
reduce the prevalence of cigarette smoking to less than
12%.28 Effective smoking-cessation programs targeting
incarcerated people are necessary to reach this goal be-

Figure 2. Tobacco abstinence at the 3-week follow-up by the study condition
group (adjusted survival curves). *Effect seen in treatment group is
significant (P=.001) (␤ [SE], 0.56 [0.16]; hazard ratio, 1.75), indicating that
the risk of smoking after release was over 1.75 times greater for those in the
control condition compared with those in the WISE (Working Inside for
Smoking Elimination11) intervention.

cause approximately 9 million individuals (⬎5.4 million smokers) return to the community from correctional facilities annually.4 Tobacco use among prisoners
is approximately 3 times that of the general population.7 Smoking-cessation interventions targeting this highrisk and underserved population are instrumental to decrease health disparities and decrease tobacco-related
illnesses in this vulnerable population.
Further investigation is needed. Our study’s strengths
include a diverse population (52% non-Hispanic whites),
inclusion of all smokers regardless of motivation to remain abstinent after release, cotinine verification of smoking status, and a follow-up rate over 90%. The study’s
limitations include follow-up after release from prison
limited to 3 weeks for all participants; however, participants not smoking at the 3-week follow-up visit were invited to follow up at 3 months after release to assess for
continuous abstinence. Because this is the first study of
this population, and relapse rates are precipitously high
immediately after release, we believed that a brief follow-up period for all participants was appropriate, with
longer follow-up of the nonsmokers. Further investigation with longer postrelease follow-up is needed. Also,
the study was limited to a sentenced population. Many
of the 9 million people released from prisons and jails
every year have been imprisoned there for less than 3
months and do not have specific release dates. Evaluations of smoking cessation interventions are needed for
inmates at the time of entry to prisons and jails.
In summary, our study shows that an intervention
based on MI and CBT can improve continued smoking
abstinence after prison release by 6.6 times over that of
the control condition. Behavioral intervention for drug
use is common in prison settings,29 and so this intervention may be easily integrated into and transported to existing programs in prison settings. Future studies may
wish to dismantle the treatment to streamline into the
most effective components. Additional work is also needed
to examine methods for providing postrelease intervention to help sustain longer-term abstinence.
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